SAN FRANCISCO, Oct. 19, 2016 /PRNewswire/ -- Symic Bio, a clinical stage biopharmaceutical company developing a new category of therapeutics focused on extracellular matrix biology, today announced that Morten Karsdal, Ph.D., has been appointed as a member of the company’s Scientific Advisory Board.
“Dr. Karsdal is well recognized for his expertise in biomarker development, including biomarkers that reflect connections between the extracellular matrix and disease biology. In addition, his support has been integral to Symic Bio’s collaboration with Nordic Bioscience in the clinical development of SB-061 for osteoarthritis,” said Seema Kantak, Chief Scientific Officer of Symic Bio. “We are extremely pleased to have Dr. Karsdal contribute even more to our mission by accepting this position.”
“Symic Bio has a distinctive platform for developing therapies that address disease biology from a perspective that begins outside of the cell, and has made great strides in clinical development,” said Dr. Karsdal. “I’m glad to be able to work more closely with a world-class, fully committed group of researchers and drug developers.”
Dr. Morten Karsdal, Ph.D., serves as CEO of Nordic Bioscience, a position he has held since 2010 following multiple positions at Nordic Bioscience beginning in 2001. In addition, Dr. Karsdal holds the position of Adjunct Professor at the University of Southern Denmark and has published extensively, contributing to over 165 peer-reviewed articles in the areas of osteoarthritis, fibrosis and inflammation. Dr. Karsdal received a Ph.D. in Bone and Cartilage Pharmacology from the University of Southern Denmark.
About Symic Bio
Symic Bio is a clinical stage biopharmaceutical company developing a new category of therapeutics focused on extracellular matrix biology. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules of the extracellular matrix. Symic Bio currently has two clinical candidates, one for the treatment of critical limb ischemia (SB-030) and one directed at disease-modification in the treatment of osteoarthritis (SB-061). In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system.
For additional information please visit the company’s website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio/ or follow on Twitter at www.twitter.com/symicbio.
Media Contacts
David Schull or Rich Allan
Russo Partners, LLC
(212) 845-4271
(646) 942-5588
david.schull@russopartnersllc.com
rich.allan@russopartnersllc.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/symic-bio-appoints-morten-karsdal-phd-to-scientific-advisory-board-300345862.html
SOURCE Symic Bio
